Hyderabad, Jan. 24: Bharat Biotech International Limited (BBIL) has received Korean Food and Drugs Administration (KFDA) approval for its state-of-the-art manufacturing facility near Hyderabad. Announcing this at a press conference here on Monday, Krishna M. Ella, Chairman and Managing Director, said the company could now manufacture and export human vaccines to Korea, one of the regulated markets. It had already bagged Rs 2 crore order for exporting preservation free vaccines.

Mr. Ella said BBIL becomes the first pharma-biotech company in the country to be audited and approved by the Korean FDA. So far very few Indian companies were successful in manufacturing and exporting injectables to the U.S. and Europe. This is the first time that a preservative-free vaccine has been moved out of the U.S. to be manufactured in India at Bharat Biotech.